H R Lijnen|B Van Hoef|D Collen - JoVE Visualize

Showing results (11-20 of 610) with videos related to

Pageof 61

Sort By:

European Journal of Biochemistry|January 15, 1987

Differential reactivity of Glu-Gly-Arg-CH2Cl, a synthetic urokinase inhibitor, with single-chain and two-chain forms of urokinase-type plasminogen activatorH R Lijnen, B Van Hoef, D Collen

European Journal of Biochemistry|November 1, 1996

Characterization of the murine plasminogen/urokinase-type plasminogen-activator systemH R Lijnen, B Van Hoef, D Collen

Thrombosis Research|July 1, 1982

Purification and partial primary structure of cyanogen bromide fragments from human alpha 2-antiplasminH R Lijnen, B Wiman, B van Hoef, et al.

Biochimica Et Biophysica Acta|January 9, 1992

On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrinH R Lijnen, B Van Hoef, O Matsuo, et al.

The Journal of Biological Chemistry|March 25, 1990

Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu)H R Lijnen, B Van Hoef, L Nelles, et al.

Blood|April 16, 1998

Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in miceH R Lijnen, J Silence, B Van Hoef, et al.

Journal of Thrombosis and Haemostasis : JTH|January 14, 2004

Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1)H R Lijnen, B Van Hoef, K Umans, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|June 10, 2000

Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injuryH R Lijnen, B Van Hoef, M Dewerchin, et al.

European Journal of Biochemistry|September 15, 1994

Characterization of the murine plasma fibrinolytic systemH R Lijnen, B van Hoef, V Beelen, et al.

Thrombosis and Haemostasis|August 31, 1984

Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technologyC Zamarron, H R Lijnen, B Van Hoef, et al.

Pageof 61

Showing results (11-20 of 610) with videos related to

Sort By:

Pageof 61

European Journal of Biochemistry|January 15, 1987

Differential reactivity of Glu-Gly-Arg-CH2Cl, a synthetic urokinase inhibitor, with single-chain and two-chain forms of urokinase-type plasminogen activatorH R Lijnen, B Van Hoef, D Collen

European Journal of Biochemistry|November 1, 1996

Characterization of the murine plasminogen/urokinase-type plasminogen-activator systemH R Lijnen, B Van Hoef, D Collen

Thrombosis Research|July 1, 1982

Purification and partial primary structure of cyanogen bromide fragments from human alpha 2-antiplasminH R Lijnen, B Wiman, B van Hoef, et al.

Biochimica Et Biophysica Acta|January 9, 1992

On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrinH R Lijnen, B Van Hoef, O Matsuo, et al.

The Journal of Biological Chemistry|March 25, 1990

Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu)H R Lijnen, B Van Hoef, L Nelles, et al.

Blood|April 16, 1998

Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in miceH R Lijnen, J Silence, B Van Hoef, et al.

Journal of Thrombosis and Haemostasis : JTH|January 14, 2004

Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1)H R Lijnen, B Van Hoef, K Umans, et al.

Arteriosclerosis, Thrombosis, and Vascular Biology|June 10, 2000

Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injuryH R Lijnen, B Van Hoef, M Dewerchin, et al.

European Journal of Biochemistry|September 15, 1994

Characterization of the murine plasma fibrinolytic systemH R Lijnen, B van Hoef, V Beelen, et al.

Thrombosis and Haemostasis|August 31, 1984

Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technologyC Zamarron, H R Lijnen, B Van Hoef, et al.

Pageof 61